M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot PharmaphorumSpero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R D.Immunology & InflammationRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) Pharmaphorum Spero has licensed rights to an anti-CD40L antibody developed by China’s Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R D. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5BNext: Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
